Jan Keltjens Appointed to Board of Directors of AngioDynamicsQUEENSBURY, N.Y.--(BUSINESS WIRE)--May. 11, 2009--
AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative
medical devices used by interventional radiologists and surgeons for the
minimally-invasive treatment of cancer and peripheral vascular disease,
today announced Jan Keltjens, 52, President and Chief Executive Officer
of the Company, has been appointed to its Board of Directors. Mr.
Keltjens replaces
Eamonn Hobbs, who has resigned from the Board of
Directors.
“On behalf of the Board of Directors, I would like to thank Eamonn for
all his contributions to AngioDynamics, both as the company’s co-founder
and previous chief executive officer, as well as most recently as a
member of the Board. We all wish him the very best in his future
endeavors,” said Vincent Bucci, Chairman of the Board of Directors. “At
the same time, the Board looks forward to working with Jan in his
expanded role with AngioDynamics. During his short tenure as our
president and chief executive officer, his performance has reinforced
the Board’s confidence in his leadership of the Company.”
Mr. Keltjens joined AngioDynamics as President and CEO on March 1, 2009.
Most recently, he was President and CEO of CryoCath Technologies, Inc.
Mr. Keltjens also previously served in various leadership positions at
Cordis, a Johnson & Johnson company, including his last position as
Worldwide General Manager of Cordis Neurovascular.
About AngioDynamics
AngioDynamics, Inc. is a leading provider of innovative medical devices
used by interventional radiologists, surgeons and other physicians for
the minimally-invasive treatment of cancer and peripheral vascular
disease. The Company’s diverse product line includes market-leading
radiofrequency and irreversible electroporation ablation systems,
vascular access products, angiographic products and accessories,
dialysis products, angioplasty products, drainage products, thrombolytic
products, embolization products and venous products. More information is
available at www.angiodynamics.com.
Source: AngioDynamics, Inc.
AngioDynamics, Inc.
D. Joseph Gersuk, CFO, 800-772-6446 ext. 1608
jgersuk@AngioDynamics.com
or
EVC
Group, Inc.
Doug Sherk, 415-896-2005 (Investor Relations)
dsherk@evcgroup.com
Jenifer
Kirtland, 415-896-2005 (Investor Relations)
jkirtland@evcgroup.com
Chris
Gale, 646-201-5431 (Media)
cgale@evcgroup.com
Steve
DiMattia, 646-201-5431 (Media)
sdimattia@evcgroup.com